Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PR Newswire - Thu May 28, 5:30AM CDT

– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –

IMUX : 14.17 (-3.21%)
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer PR Newswire - Wed May 27, 5:30AM CDT

– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus ® –

IMUX : 14.17 (-3.21%)
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors PR Newswire - Tue May 19, 5:30AM CDT

– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –

IMUX : 14.17 (-3.21%)
Immunic: Q1 Earnings Snapshot AP - Wed May 13, 5:35AM CDT

Immunic: Q1 Earnings Snapshot

IMUX : 14.17 (-3.21%)
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire - Wed May 13, 5:30AM CDT

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –

IMUX : 14.17 (-3.21%)
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer PR Newswire - Tue Apr 28, 5:30AM CDT

– Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies –

IMUX : 14.17 (-3.21%)
Immunic, Inc. Announces 1-for-10 Reverse Stock Split PR Newswire - Thu Apr 23, 7:00AM CDT

NEW YORK , April 23, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...

IMUX : 14.17 (-3.21%)
Immunic to Participate in Scientific and Medical Conferences in April PR Newswire - Thu Apr 9, 5:30AM CDT

NEW YORK , April 9, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

IMUX : 14.17 (-3.21%)
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire - Wed Apr 1, 5:30AM CDT

NEW YORK , April 1, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX) ,  a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...

IMUX : 14.17 (-3.21%)
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton PR Newswire - Tue Mar 31, 5:30AM CDT

– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –

IMUX : 14.17 (-3.21%)

Barchart Exclusives

Dear Dividend Investors, Mark Your Calendars for June 23 Barchart - Wed Jun 3, 6:30PM CDT
FedEx is expected to announce its sixth consecutive dividend hike with Q4 results scheduled on 23 June. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.